Cervical cancer historical perspective

Jump to navigation Jump to search

Cervical cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cervical Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cervical Cancer During Pregnancy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cervical cancer historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cervical cancer historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cervical cancer historical perspective

CDC on Cervical cancer historical perspective

Cervical cancer historical perspective in the news

Blogs on Cervical cancer historical perspective

Directions to Hospitals Treating Cervical cancer

Risk calculators and risk factors for Cervical cancer historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

History

  • 400 BCE - Hippocrates noted that cervical cancer was incurable
  • Epidemiologists working in the early 20th century noted that cervical cancer behaved like a sexually transmitted disease.
  • In summary:
  • Cervical cancer was noted to be common in female sex workers.
  • It was rare in nuns, except for those who had been sexually active before entering the convent. (Rigoni in 1841)
  • It was more common in the second wives of men whose first wives had died from cervical cancer.
  • It was rare in Jewish women.[1]
  • In 1935, Syverton and Berry discovered a relationship between RPV (Rabbit Papillomavirus) and skin cancer in rabbits. (HPV is species-specific and therefore cannot be transmitted to rabbits)[citation needed]
  • These historical observations suggested that cervical cancer could be caused by a sexually transmitted agent. Initial research in the 1940s and 1950s attributed cervical cancer to smegma (e.g. Heins et al. 1958).[2]
  • 1925 - Hinselmann invented the colposcope
  • 1928 - Papanicolaou developed the Papanicolaou technique
  • 1941 - Papanicolaou and Trout: Pap smear screening began
  • 1946 - Aylesbury spatula was developed to scrape the cervix, collecting the sample for the Pap smear
  • 1951 - First successful in-vitro cell line, HeLa, derived from biopsy of cervical cancer of Henrietta LacksA description of human papillomavirus (HPV) by electron microscopy was given in 1949, and HPV-DNA was identified in 1963.[citation needed] It was not until the 1980s that HPV was identified in cervical cancer tissue.[3]
  • 1976 - Harald zur Hausen and Gisam found HPV DNA in cervical cancer and genital warts; Hausen later won the Nobel Prize for his work[4]
  • During the 1960s and 1970s it was suspected that infection with herpes simplex virus was the cause of the disease. In summary, HSV was seen as a likely cause because it is known to survive in the female reproductive tract, to be transmitted sexually in a way compatible with known risk factors, such as promiscuity and low socioeconomic status.[5] Herpes viruses were also implicated in other malignant diseases, including Burkitt's lymphoma, Nasopharyngeal carcinoma, Marek's disease and the Lucké renal adenocarcinoma. HSV was recovered from cervical tumour cells.
It has since been demonstrated that HPV is implicated in virtually all cervical cancers.[6] Specific viral subtypes implicated are HPV 16, 18, 31, 45 and others.

In work that was initiated in the mid 1980s, the HPV vaccine was developed, in parallel, by researchers at Georgetown University Medical Center, the University of Rochester, the University of Queensland in Australia, and the U.S. National Cancer Institute.[7]

In 2006, the U.S. Food and Drug Administration (FDA) approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil.

References

  1. Menczer J (2003). "The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved?" (PDF). Isr. Med. Assoc. J. 5 (2): 120–3. PMID 12674663.
  2. Heins HC, Dennis EJ, Pratthomas HR (1958). "The possible role of smegma in carcinoma of the cervix". American Journal of Obstetrics & Gynecology. 76 (4): 726–33. PMID 13583012.
  3. Dürst M, Gissmann L, Ikenberg H, zur Hausen H (1983). "A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions". Proceedings of the National Academy of Sciences of the United States of America. 80 (12): 3812–5. doi:10.1073/pnas.80.12.3812. PMC 394142. PMID 6304740..
  4. zur Hausen, Harald (2002). "Papillomaviruses and cancer: from basic studies to clinical application". Nature Reviews Cancer. 2 (5): 342–350. doi:10.1038/nrc798. ISSN 1474-1768.
  5. Alexander ER (1973). "Possible Etiologies of Cancer of the Cervix Other Than Herpesvirus". Cancer Research. 33 (6): 1485–90. PMID 4352386.
  6. Lowy DR, Schiller JT (2006). "Prophylactic human papillomavirus vaccines". J. Clin. Invest. 116 (5): 1167–73. doi:10.1172/JCI28607. PMC 1451224. PMID 16670757.
  7. McNeil C (April 2006). "Who invented the VLP cervical cancer vaccines?". J. Natl. Cancer Inst. 98 (7): 433. doi:10.1093/jnci/djj144. PMID 16595773. PMID 16595773

Template:WH Template:WS